Clinical Trial Update: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a triple combination of sintilimab, IBI310, and surufatinib for high-grade neuroendocrine tumors and neuroendocrine carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Neoplasm | Phase 2 | Status: RECRUITING